Physician
Medicine/Pediatrics
Dr. Vivek Subbiah, MD
|
|
Give Review
Vivek Subbiah, MD is an expert in the field of Medicine/Pediatrics. He researched medicine at Sri Ramachandra Medical College. Vivek Subbiah is a published doctor. He published 34 publications, including: 'Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary Bladder reveals a high frequency of clinically relevant genomic...
- Clinical activity of ceritinib in ROS1-rearranged non-small cell lung Cancer: Bench to bedside report.
- Headache in a patient with Renal cell carcinoma.
- Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
- Personalized comprehensive molecular profiling of high risk Osteosarcoma: Implications and limitations for precision medicine.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic Tumors.
- Targeted therapy for genetic Cancer syndromes: Fanconi anemia, medullary thyroid Cancer, tuberous sclerosis, and RASopathies.
- Targeted therapy for genetic Cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.
- Exceptional responders: in search of the science behind the miracle Cancer cures.
- Targeted therapy for hereditary Cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.
- Targeted therapy for hereditary Cancer syndromes: hereditary breast and ovarian Cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's Lymphoma.
- A tale of two histiocytic Disorders.
- Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell Leukemia and Langerhans/dendritic cell sarcoma.
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist.
- Ewing's sarcoma: overcoming the therapeutic plateau.
- Radium-223 dichloride therapy in breast Cancer with osseous metastases.
- A framework for genomic biomarker actionability and its use in clinical decision making.
- Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast Cancer metastatic to bone.
- Targeted therapy by combined inhibition of the RAF and mTOR kinases in Malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Comprehensive characterization of Malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
- Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing's Sarcoma (EWS/FLI1) an...
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory Cancers.
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- AdRenal Gland Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Medicine/Pediatrics
Accepted Insurances
Education
-
University of Texas Health Science Center -
Case Western Reserve University - MetroHealth -
Sri Ramachandra Medical College
Drug Facts
| NPI NUMBER | 1174726384 | |
| NPPES Provider LastName | SUBBIAH | |
| NPPES Provider FirstName | VIVEK | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 248.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174726384 |
| Last Name Of The Provider | SUBBIAH |
| First Name Of The Provider | VIVEK |
| View All |
Similar Doctors
|
|
Dr. Elinor Lee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad R. Niemeyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Tsao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imad Shureiqi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amin M. Alousi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. An N. Hoang, MD |
|
|
Dr. Surya N. Mulukutla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dhaval Parekh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia Peacock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison M. Blazek, MD
This Doctor is OpenDoctor Recommended.
|